Based on the results of the present and previous studies, the next progression of research into DR3-targeted therapies is to construct a targeted small hairpin RNA (shRNA) plasmid vector of the DR3 gene and cultivate stable DR3 silenced hepatocarcinoma cell lines for nude mice experiments in vitro. These experiments will aim to compare DR3 −/− and high expressing DR3 liver cancer cell tumorigenicity and metastatic ability. This evidence concerns the gene TNFRSF25 and liver cancer.